1635: Prostate Specific Antigen (PSA) and Post Void Residual (PVR) Urine Volume Predict Relapse of Urinary Retention and Need for Surgery in Patients with Benign Prostatic Hyperplasia (BPH) After a First Episode of Acute Urinary Retention (AUR)

2005 ◽  
Vol 173 (4S) ◽  
pp. 442-443
Author(s):  
Claus G. Roehrborn ◽  
Tim B. Hargreave ◽  
S. Alan McNeill ◽  
Amy Naadimuthu ◽  
Jean-Luc Beffy
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Urinary Retention ◽  
Prostate Specific Antigen ◽  
Acute Urinary Retention ◽  
Specific Antigen ◽  
Urine Volume ◽  
Prostatic Hyperplasia ◽  
First Episode

scholarly journals Monotherapy versus combination therapy in the treatment of benign prostatic hyperplasia: A single center study

2020 ◽  
Vol 24 (3) ◽  
pp. 333-337
Author(s):  
Wishyar Al-Bazzaz ◽  
Omar Alkhayat ◽  
Ali AlKhayat
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Combination Therapy ◽  
Urinary Retention ◽  
Prostate Specific Antigen ◽  
Acute Urinary Retention ◽  
Prostate Volume ◽  
Combined Treatment ◽  
Specific Antigen ◽  
Prostatic Hyperplasia ◽  
Once Daily

Background and objectives: Most benign prostatic hyperplasia patients do not present obvious indicators for surgical intervention, so most of these patients are treated initially with medical therapy. This study aimed to compare the incidence of acute urinary retention after treatment with monotherapy with the incidence after combination therapy and determine the need for surgery in both methods. Methods: This is a retrospective study of the medical records of 248 benign prostatic hyperplasia patients who had attended Rizgary Teaching Hospital from May 2012 to June 2017. These patients were divided into two groups of 138 and 110 patients who have been treated by 0.4 mg tamsulosin capsule once daily and 0.4 mg tamsulosin capsule plus 5mg finasteride tablet once daily, respectively. Benign prostatic hyperplasia outcomes (acute urinary retention, benign prostatic hyperplasia related surgery) were compared between these two groups according to prostate volume and serum prostate specific antigen. Results: The combined treatment had significantly reduced the incidence of acute urinary retention and benign prostatic hyperplasia related surgery than monotherapy (P = 0.006 and 0.044, respectively). Similarly, when prostate volume and prostate specific antigen were above the cutoff value, both acute urinary retention and benign prostatic hyperplasia related surgery were lower in the combination therapy group than the monotherapy group. Conclusion: Combined therapy (0.4 mg tamsulosin plus 5mg finasteride) was significantly superior to 0.4 mg tamsulosin alone in the reduction of the incidence of acute urinary retention and benign prostatic hyperplasia related surgery among benign prostatic hyperplasia patients. Keywords: Benign prostatic hyperplasia; Acute urinary retention; Benign prostatic hyperplasia related surgery; Prostate volume; Prostate specific antigen.

scholarly journals Relationship of Prostate-Specific Antigen (PSA) and Prostate Volume in Patients with Biopsy Proven Benign Prostatic Hyperplasia (BPH)

2020 ◽  
Vol 4 (2) ◽  
pp. 171
Author(s):  
Aulia Nur Fadila ◽  
Anny Setijo Rahaju ◽  
Tarmono Tarmono
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Prostate Specific Antigen ◽  
Acute Urinary Retention ◽  
Prostate Volume ◽  
Specific Antigen ◽  
Prostatic Hyperplasia ◽  
Benign Tumors ◽  
Relationship Of ◽  
The Relationship ◽  
Histopathology Examination

Abstract  Benign prostatic hyperplasia (BPH) is one of the most common benign tumors in men with prevalence ranging from 50% for men in their 60s to 90% for men in their 80s. The researcher sought to determine the relationship of prostate-specific antigen (PSA) and prostate volume in patients with benign prostatic hyperplasia. This study was based on 33 cases of benign prostatic hyperplasia in the Department of Urology, RSUD Dr. Soetomo Surabaya that diagnosed by histopathology examination. Cases with malignancy, acute urinary retention and prostatitis were excluded. The variables of prostate-specific antigen and prostate volume were examined. The results of this study found that 33 men were enrolled with mean PSA 16,04 ng/ml and a mean prostate volume of 49,13 ml. Overall, 84,8% had PSA level >4 ng/ml and 90,9% had prostate volume >25 ml. Prostate-specific antigen has significant correlation with prostate volume (p=0,019; r=0,362). This study concluded that prostate-specific antigen and prostate volume showed a significant correlation. Keywords             : benign prostatic hyperplasia, prostate specific antigen, prostate volumeCorrespondence   : [email protected]

scholarly journals Efficacy and Safety of Silodosin and Dutasteride Combination Therapy in Acute Urinary Retention due to Benign Prostatic Hyperplasia: A Single-Arm Prospective Study

2016 ◽  
Vol 2016 ◽  
pp. 1-5 ◽  
Author(s):  
Kazuhisa Hagiwara ◽  
Takuya Koie ◽  
Hiromichi Iwamura ◽  
Atsushi Imai ◽  
Shingo Hatakeyama ◽  
...  
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Combination Therapy ◽  
Urinary Retention ◽  
Acute Urinary Retention ◽  
Prostatic Hyperplasia ◽  
First Episode ◽  
Urinary Flow ◽  
Daily Trial ◽  
Postvoid Residual Urine

This study aimed to assess the efficacy of combination therapy with dutasteride and silodosin in patients with acute urinary retention (AUR) caused by benign prostatic hyperplasia (BPH). Eighty consecutive patients with a first episode of AUR were enrolled in this study. All patients received silodosin 8 mg and dutasteride 0.5 mg daily. Trial without catheter (TWOC) was attempted every 2 weeks until 12 weeks after the initiation of medication. The primary endpoint was the rate of catheter-free status at 12 weeks. Voided volume (VV), postvoid residual urine (PVR), uroflowmetry, International Prostatic Symptoms Score (IPSS), and quality of life due to urinary symptoms (IPSS-QOL) were also measured. All patients were followed up for more than 12 weeks and were included in this analysis. The success rate of TWOC at 12 weeks was 88.8%. VV and maximum urinary flow rate were significantly higher at 2, 4, 8, and 12 weeks compared with the time of AUR (P<0.001). IPSS and IPSS-QOL were significantly lower at 2, 4, 8, and 12 weeks compared with the time of AUR (P<0.001). In conclusion, a combination of dutasteride and silodosin therapy may be effective and safe for patients with AUR due to BPH.

MODELING AN APPROACH TO THE TREATMENT OF ACUTE URINARY RETENTION IN BENIGN PROSTATIC HYPERPLASIA

2020 ◽  
Vol 22 (4) ◽  
pp. 82-87
Author(s):  
S.M. Pikalov ◽  
A.A. Zimichev ◽  
D.O. Gusev ◽  
P.V. Sumsky ◽  
A.D. Adilov ◽  
...  
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Urinary Retention ◽  
Acute Urinary Retention ◽  
Prostatic Hyperplasia

scholarly journals Safety and efficacy of prostatic artery embolization for large benign prostatic hyperplasia in elderly patients

2021 ◽  
Vol 49 (1) ◽  
pp. 030006052098628
Author(s):  
Chen Xu ◽  
Gang Zhang ◽  
Jin-jin Wang ◽  
Chun-xian Zhou ◽  
Min-jun Jiang
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Elderly Patients ◽  
Prostate Volume ◽  
Specific Antigen ◽  
Urine Volume ◽  
Prostatic Hyperplasia ◽  
Antigen Level ◽  
Residual Urine Volume ◽  
Safety And Efficacy ◽  
Total Prostate Specific Antigen

Objective To assess the safety and efficacy of prostatic arterial embolization (PAE) for elderly patients with lower urinary tract symptoms secondary to large benign prostatic hyperplasia. Methods Twenty-eight patients (>80 years of age) with prostate volume >80 mL were enrolled from October 2016 to October 2019. PAE was performed using microspheres and functional results were evaluated at 1, 3, 6, and 12 months postoperatively. The following data were recorded: International Prostate Symptom Score (IPSS), quality of life (QoL), maximum urine flow rate (Qmax), post-void residual urine volume, prostate volume and total prostate-specific antigen level. Results Selective prostatic arterial catheterization and embolization were achieved in 27 of 28 patients. Follow-up data were available for those 27 patients until 12 months postoperatively. Significant improvements were found at all postoperative time points in terms of the mean IPSS, mean QoL score, mean Qmax, mean post-void residual urine volume, mean total prostate-specific antigen level, and mean prostate volume. The overall complication rate was 46.4%. Conclusions PAE is an efficacious and safe treatment for elderly patients with large prostate volume; it may offer an effective approach for patients who are not candidates for open or endoscopic surgical procedures because of comorbidities.

Sign in / Sign up

Export Citation Format

Share Document